Document Detail


Implantation of a drug delivery system during surgery for patients with primary hepatocarcinoma.
MedLine Citation:
PMID:  16911937     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Postoperative regional chemotherapy is one of the most effective methods to decrease the recurrent rate and improve the prognosis of primary hepatocarcinoma (PHC). This study was undertaken to assess the optimal pathway to implant the drug delivery system (DDS) in the different ways of resecting PHC so as to offer a valuable reference to clinical implantation of the DDS. METHODS: One hundred and ninety cases were divided into two groups according to whether the tumors were resected completely (A) or not (B). Groups A and B were subdivided into three groups a, b and c according to the pathway selected for DDS implantation. The patients in subgroup a received DDS implantation through both the hepatic artery and portal vein (A+P-implanted group), the patients in subgroup b received DDS implantation through the portal vein (P-implanted group), and the patients in subgroup c received DDS implantation through the hepatic artery (A-implanted group). RESULTS: The 1- and 3-year recurrent rates of subgroup c in group A were higher than those of subgroup b, and there was no significant difference between subgroups a and b. Compared with subgroups a and c, the 1- and 3-year survival rates of subgroup b were similar to those of group a but higher than those of group c. The 1- and 3-year survival rates between subgroups a and b in group B were significantly different. The prognosis of subgroup c was lower than that of subgroup a and no significant difference was observed between subgroups b and c. CONCLUSIONS: The DDS should be implanted into the portal vein when PHC is resected completely. It may be better to implant it into both portal vein and hepatic artery if the tumor cannot be completely resected.
Authors:
Wan-Ping Chen; Xin He; Qi-Fa Ye; Ke Li
Related Documents :
16911937 - Implantation of a drug delivery system during surgery for patients with primary hepatoc...
19329797 - A single-centre experience of over one thousand lead extractions.
15609887 - Is there a need to remove an old pacemaker when implanting a new device in the contrala...
1719497 - Experimental study about removal of the implanted tined polyurethane ventricular lead b...
23057027 - Immediate and delayed restoration of dental implants in patients with a history of peri...
16040117 - Qualitative computer aided evaluation of dental impressions in vivo.
Publication Detail:
Type:  Controlled Clinical Trial; Journal Article    
Journal Detail:
Title:  Hepatobiliary & pancreatic diseases international : HBPD INT     Volume:  5     ISSN:  1499-3872     ISO Abbreviation:  HBPD INT     Publication Date:  2006 Aug 
Date Detail:
Created Date:  2006-08-16     Completed Date:  2006-12-19     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101151457     Medline TA:  Hepatobiliary Pancreat Dis Int     Country:  China    
Other Details:
Languages:  eng     Pagination:  391-5     Citation Subset:  IM    
Affiliation:
Institute of Organ Transplantation, Third Xiangya Hospital, Xiangya Medical College, Central South University, Changsha 410013, China. wanpingchen192@yahoo.com.cn
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antineoplastic Agents / administration & dosage*
Carcinoma, Hepatocellular / drug therapy*,  surgery*
Combined Modality Therapy
Drug Implants*
Humans
Liver Neoplasms / drug therapy*,  surgery*
Middle Aged
Recurrence
Treatment Outcome
Chemical
Reg. No./Substance:
0/Antineoplastic Agents; 0/Drug Implants

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Caudate lobectomy by the third porta hepatis anatomical method: a study of 16 cases.
Next Document:  Surgical treatment for hepatocellular carcinoma and secondary hypersplenism.